"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at an antibiotic to try to prevent infections in people having treatment for myeloma (TEAMM)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at an antibiotic called levofloxacin to see if it can reduce the risk of infection in people starting treatment for myeloma.
More about this trial
Myeloma is a type of cancer that develops from cells in the
Doctors in this trial are looking to reduce risk of infection from the start, rather than waiting to see if an infection develops and then treating it. They will test an
Who can enter
You may be able to enter this trial if
- You are newly diagnosed with myeloma
- You have symptoms from your myeloma
- Your doctor is planning to start treating your myeloma in the next 2 weeks or you are no more than 2 weeks into a course of myeloma treatment
- You are willing to use reliable contraception during the trial if there is a risk that you or your partner could become pregnant
- You are at least 21 years old
You cannot enter this trial if you
- Would not be able to take levofloxacin for any reason – you can check this with your doctor
- Definitely need to take antibiotics to prevent infection (joining this trial may mean you take a dummy tablet instead of antibiotics)
- Have already had treatment for myeloma – if you have had radiotherapy to treat bone pain or damage to your spine, or had bisphosphonate treatment you may still be able to take part
- Have had any other cancer in the last 5 years, apart from very early prostate cancer (stage T1a or 1b) that was found during a routine check up in the last 5 years, or carcinoma in situ of the cervix, very early breast cancer called
in situ breast cancer, or non melanoma skin cancer that has been successfully treated (if you had cancer more than 5 years ago that was successfully treated you may also still be able to take part)
- Are pregnant or breastfeeding
This trial will recruit 1,000 people. It is randomised. The people taking part are put into one of 2 groups by a computer. Neither you nor your doctor will be able to decide or know which group you are in. This is called a double blind trial.
Everyone will start the myeloma treatment already planned for them, which is not part of the trial. If you are in group 1, you take levofloxacin for 12 weeks. If you are in group 2, you take a dummy tablet (placebo) for 12 weeks.
The trial team will show you how to take your temperature. They will give you a thermometer to take home, and a diary. You check and write down your temperature each day, and anytime you feel unwell. You will have a number to call if you develop a temperature or feel unwell, as you will need to come to hospital quickly if you get an infection.
You give regular stool samples and samples collected with a cotton bud from the inside of your nose (nasal swabs). This is important as it will help the team to see if using antibiotics every day increases the risk of healthcare related infections such as diarrhoea caused by
When you finish the trial you will continue to see your regular myeloma doctor as before.
You will see the trial team when you come to hospital for your routine myeloma appointments. So you will not have to make any extra visits to take part in this trial.
Possible side effects of levofloxacin include
- Feeling sick
- Skin rash
- Increased problems with
inflammationof the tendons(tendonitis), if you already have this condition
- An infection of the gut called clostridium difficile, causing diarrhoea
In case you are in the group taking levofloxacin you should
- Avoid being in strong sunlight or other strong UV light during the trial, as this can cause a skin reaction
- Avoid taking medication to control stomach acid (antacids) that contain iron, magnesium or aluminium for 2 hours before and after taking the trial drug
- Tell your anticoagulant clinic if you take the blood thinning drug warfarin
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Mark Drayson
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
NIHR Health Technology Assessment (HTA) programme
University of Birmingham
University of Warwick